Last updated on December 2019

A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency


Brief description of study

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Clinical Study Identifier: NCT02975934

Find a site near you

Start Over

Yale University School of Medicine

New Haven, CT United States
9.0miles
  Connect »